About the centre

Currently licensed influenza vaccines often suffer from low efficiency and time consuming production.

Why do we need novel vaccines against influenza?

Each year, novel mutations in the viral surface proteins allow the viruses to escape host immunity,  necessitating the continuous update of annual influenza vaccines. Due to the time consuming production, strains for vaccine production have to be selected almost a year in advance of vaccine deployment. In years of grave mismatches between circulating viruses and vaccine strains, vaccines have only a very low efficacy.

A further potential problem is the periodic emergence of influenza pandemics. With the extended production time for current vaccines, the population may be left with very little coverage in the event of the emergence of a pandemic virus. In order to remedy these challenges, JIV is working on development of novel strategies for prophylactic vaccination.

The aim for the Centre is to develop a single vaccine that confers life-long protection against present and future influenza viruses. The combined efforts from the 4 groups in the Centre will promote a feedback loop, where research on increased understanding of the human immune responses to influenza infection and vaccination can be combined with basic immunological research to design improved next generation influenza vaccines.

JIV consists of renowned scientists within the fields of immunology, virology and infection diseases, from the University of Oslo, Oslo University Hospital, University of Bergen and the Norwegian Institute of Public Health. The Centre thus gathers scientists with complementary competences on a common goal: the development of novel influenza vaccines.

The centre consists of four research groups headed by

  • Professor Bjarne Bogen, Dep. for Immunology and Transfusion Medicine, University of Oslo and Oslo University Hospital
  • Professor Rebecca Cox, the Influenza Centre, Department of clinical Science, University of Bergen and Dept. of Research and Development, Haukeland University Hospital
  • Professor Dag Kvale, Clinic for Medicine, University of Oslo and Oslo University Hospital
  • Professor Siri Mjaaland, Dep. for Bacteriology and Infection Immunology, Norwegian Institute of Public Health
Published Mar. 25, 2015 10:07 AM - Last modified Apr. 10, 2015 12:44 PM